Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/24/17 → 9/25/19 |
Funding
- Incyte Corporation: $17,046.00
17-HEM-10-IN (INCB-18424-365) A Phase III, randomized, open-label, multi-center Study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation
- Ramlal, Reshma (PI)